Increased FLI-1 Expression is Associated With Poor Prognosis in Non-Small Cell Lung Cancers
Increased FLI-1 Expression is Associated With Poor Prognosis in Non-Small Cell Lung Cancers
复制标题
DOI：
10.1097/pai.0000000000000227
复制
发表时间：
2016-09-01
影响因子：
1.6
通讯作者：
Chai, Chee-Yin
中科院分区：
文献类型：
--
作者：
Lin, Shiou-Fu;Wu, Chun-Chieh;Chai, Chee-Yin
Friend白血病整合1（FLI-1）抗体是一种针对FLI-1蛋白结合结构域C末端的市售抗体，已被用作鉴别诊断小蓝色圆形细胞肿瘤和血管肿瘤的有用工具，但在肺癌中表现出不一致的表达。本研究的目的是评估非小细胞肺癌（NSCLC）中FLI-1免疫组化表达及其临床病理参数与预后之间的关系。我们使用多个肿瘤微阵列研究了 108 例 NSCLC 病例中 FLI-1 的表达。分析FLI-1表达与临床病理参数和预后意义之间的相关性。通过 Kaplan-Meier 生存分析和 Cox 比例风险模型估计 FLI-1 表达对生存的影响。我们的结果显示，FLI-1 高表达患者的总生存期短于 FLI-1 低表达患者（P=0.014）。在多变量分析中，FLI-1被证实是NSCLC的独立不良预后因素（总生存期：风险比，7.292；95%置信区间，0.294-0.823；P=0.007）。总之，本研究表明FLI-1在不同亚型的NSCLC中表达不同，其表达与临床病理参数和较差的预后相关。然而，需要进一步的研究来阐明其在 NSCLC 肿瘤发生中的功能。
Friend leukemia integration-1 (FLI-1) antibody, a commercially available antibody directed against the C-terminus of FLI-1 protein-binding domain, has been used as a useful tool in the differential diagnosis of small blue round cell tumors and vascular neoplasms, but shows inconsistent expression in lung cancers. The aims of this study were to evaluate FLI-1 immunohistochemical expression in non-small cell lung cancer (NSCLC), and its relationships between the clinicopathologic parameters and prognosis. We investigated the FLI-1 expression in 108 cases of NSCLC by using multiple tumor microarrays. Correlations between the FLI-1 expression and clinicopathologic parameters and prognostic significance were analyzed. The effect of FLI-1 expression on survival is estimated by Kaplan-Meier survival analysis and Cox proportional hazards models. Our results revealed that patients with high FLI-1 expression had shorter overall survival (P=0.014) than those with low FLI-1 expression. In multivariate analysis, FLI-1 was confirmed as an independent poor prognostic factor in NSCLC (overall survival: hazard ratio, 7.292; 95% confidence interval, 0.294-0.823; P=0.007). In conclusion, this study shows that FLI-1 is expressed variably in different subtypes of NSCLC, and its expression is related to clinicopathologic parameters and poorer prognosis. However, further studies are required to elucidate its function in tumorigenesis of NSCLC.